Publications by authors named "Naoki Teno"

Claim this Profile
F
FLG249 Exhibits FXR Antagonist Activity by Inducing Dissociation of Both Corepressors and Coactivators from FXR.
Yusuke Iguchi, Yukiko Yamashita, Keigo Gohda, Ko Fujimori, Yukihiro Sera, Naoki Teno

Biol Pharm Bull· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FXR Activation Accelerates Early Phase of Osteoblast Differentiation Through COX-2-PGE-EP4 Axis in BMP-2-Induced Mouse Mesenchymal Stem Cells.
Ko Fujimori, Yusuke Iguchi, Yukiko Yamashita, Keigo Gohda, Naoki Teno

Molecules· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
FXR Antagonist FLG249 Lowers Hepatic Triacylglycerol and Serum Cholesterol Level in High-Fat Diet-Induced Obese Mice.
Yusuke Iguchi, Yukiko Yamashita, Keigo Gohda, Keisuke Oda, Ko Fujimori, Naoki Teno

Biol Pharm Bull· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of FXR/PPARγ dual partial agonist.
Yukiko Yamashita, Keigo Gohda, Yusuke Iguchi, Ko Fujimori, Keisuke Oda, Naoki Teno

Bioorg Med Chem· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and identification of a new farnesoid X receptor (FXR) partial agonist by computational structure-activity relationship analysis: Ligand-induced H8 helix fluctuation in the ligand-binding domain of FXR may lead to partial agonism.
Keigo Gohda, Yusuke Iguchi, Arisa Masuda, Ko Fujimori, Yukiko Yamashita, Naoki Teno

Bioorg Med Chem Lett· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Orally Active and Nonsteroidal Farnesoid X Receptor (FXR) Antagonist with Propensity for Accumulation and Responsiveness in Ileum.
Naoki Teno, Yusuke Iguchi, Keisuke Oda, Yukiko Yamashita, Arisa Masuda

ACS Med Chem Lett· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-Substituted benzimidazole scaffold for farnesoid X receptor (FXR) agonists accompanying prominent selectivity against vitamin D receptor (VDR).
Arisa Masuda, Keigo Gohda, Yusuke Iguchi, Ko Fujimori, Yukiko Yamashita, Naoki Teno

Bioorg Med Chem· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis of Novel Farnesoid X Receptor Agonists and Validation of Their Efficacy in Activating Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Osteoblasts.
Ko Fujimori, Yusuke Iguchi, Yukiko Yamashita, Keigo Gohda, Naoki Teno

Molecules· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of potent farnesoid X receptor (FXR) antagonist showing favorable PK profile and distribution toward target tissues: Comprehensive understanding of structure-activity relationship of FXR antagonists.
Naoki Teno, Yukiko Yamashita, Arisa Masuda, Yusuke Iguchi, Keisuke Oda

Bioorg Med Chem· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonacidic Chemotype Possessing -Acylated Piperidine Moiety as Potent Farnesoid X Receptor (FXR) Antagonists.
Naoki Teno, Yukiko Yamashita, Yusuke Iguchi, Ko Fujimori, Mizuho Une

ACS Med Chem Lett· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and optimization of benzimidazole derivatives as a novel chemotype of farnesoid X receptor (FXR) antagonists.
Naoki Teno, Yusuke Iguchi, Yukiko Yamashita, Nobuhiro Mori, Mizuho Une

Bioorg Med Chem· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Plasmin inhibitors with hydrophobic amino acid-based linker between hydantoin moiety and benzimidazole scaffold enhance inhibitory activity.
Naoki Teno, Keigo Gohda, Yukiko Yamashita, Tadamune Otsubo, Masafumi Yamaguchi

Bioorg Med Chem Lett· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Active site-directed plasmin inhibitors: Extension on the P2 residue.
Koushi Hidaka, Keigo Gohda, Naoki Teno, Keiko Wanaka, Yuko Tsuda

Bioorg Med Chem· February 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel type of plasmin inhibitors: providing insight into P4 moiety and alternative scaffold to pyrrolopyrimidine.
Naoki Teno, Keigo Gohda, Keiko Wanaka, Yuko Tsuda, Maiko Akagawa

Bioorg Med Chem· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin.
Naoki Teno, Keigo Gohda, Keiko Wanaka, Yuko Tsuda, Takuya Sueda

Bioorg Med Chem· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthetic substrates specific to activated plasmin can monitor the enzymatic functional status in situ in breast cancer cells.
Keigo Gohda, Ko Fujimori, Naoki Teno, Keiko Wanaka, Yuko Tsuda

Chem Biol Drug Des· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Ag- and Au-catalyzed addition of alcohols to ynimides: β-regioselective carbonylation and production of oxazoles.
Takuya Sueda, Arisa Kawada, Yumi Urashi, Naoki Teno

Org Lett· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and evaluation of tripeptidic plasmin inhibitors with nitrile as warhead.
Naoki Teno, Tadamune Otsubo, Keigo Gohda, Keiko Wanaka, Takuya Sueda

J Pept Sci· October 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicting subsite interactions of plasmin with substrates and inhibitors through computational docking analysis.
Keigo Gohda, Naoki Teno, Keiko Wanaka, Yuko Tsuda

J Enzyme Inhib Med Chem· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of novel plasmin inhibitors possessing nitrile moiety as warhead.
Naoki Teno, Keigo Gohda, Keiko Wanaka, Takuya Sueda, Yuko Tsuda

Bioorg Med Chem Lett· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-Alkynyl imides (ynimides): synthesis and use as a variant of highly labile ethynamine.
Takuya Sueda, Ayumi Oshima, Naoki Teno

Org Lett· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Orally bioavailable cathepsin K inhibitors with pyrrolopyrimidine scaffold.
Naoki Teno, Keiichi Masuya

Curr Top Med Chem· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The medicinal chemistry of the cathepsin cysteine proteases.
Keiichi Masuya, Naoki Teno

Curr Top Med Chem· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Small molecules for bone diseases.
Keiichi Masuya, Naoki Teno

Expert Opin Ther Pat· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overcoming hERG issues for brain-penetrating cathepsin S inhibitors: 2-cyanopyrimidines. Part 2.
Osamu Irie, Takatoshi Kosaka, Masashi Kishida, Junichi Sakaki, Keiichi Masuya, Naoki Teno

Bioorg Med Chem Lett· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis